FCGR3A and neoplasm: Since the production of IFN-γ could contribute to the overall anti-tumor effect of NK cells, we investigated whether the response could be enhanced by using clinically applicable ADCC-mediating antibodies that engage CD16, a powerful activating receptor on NK cells [20].